KDM4A promotes the progression of neuroendocrine prostate cancer
C. S. L. Mak, M. Zhu, X. Liang, F. Wang, F. Yuan, A. G. Hoang, X. Song, P. Shepherd, D. Liang, J. Suh, B. Pradhan, J. Park, M. Zhang, E. Metzger, R. Schule, , G. Wang
This study identifies KDM4A as a key driver of neuroendocrine prostate cancer progression and shows that targeting KDM4A inhibits tumor growth in preclinical models.
bioRxiv · May 14, 2022 · PreprintCancer Biology